J
Jessie Zou
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 2
Citations - 5123
Jessie Zou is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 2, co-authored 2 publications receiving 4457 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
Ann-Lii Cheng,Zhongzhen Guan,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Tsai Sheng Yang,Won Young Tak,Hongming Pan,Shiying Yu,Jianming Xu,Fang Fang,Jessie Zou,Giuseppe Lentini,D. Voliotis,Yoon-Koo Kang +15 more
TL;DR: Experimental analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status, and the efficacy and safety profiles in the subpopulations described were comparable with those in the overall study population.